Our mission
Coherent Raman imaging for biomedical solutions
Advancing biological understanding and decision-making requires a new standard in imaging—one that combines precision, speed, and reproducibility. By integrating pioneering laser technology, computational imaging, and AI, we deliver high-resolution, real-time insights into the molecular composition of tissues and cells, enabling clearer interpretation and seamless data sharing.
Our platform is built on a non-invasive, label-free approach that preserves the native state of biological samples while reducing time, complexity, and cost. This foundation supports our four key pillars—cytology and digital pathology, environmental and microplastics analysis, medical diagnostics, and pharmaceutical quality—each addressing critical challenges with a unified technology designed to improve accuracy, reliability, and impact across applications.
What we do
Our four pillars
bubble_chart
Biology and cytology
Advancing cytology and biological analysis requires moving beyond the limitations of conventional staining, which can introduce variability, depend heavily on operator technique, and alter the native structure of cells.
Coherent Raman Imaging enables a new approach by directly probing the intrinsic molecular composition of cells in real time. This label-free technology captures the biochemical fingerprint of lipids, proteins, and nucleic acids, providing quantitative and highly reproducible data. The result is faster, more objective identification and classification of cellular populations, while preserving the integrity of the biological sample.
water_drop
Environment and microplastics, enabling safer food and water
Addressing the growing challenge of microplastics is essential to protect environmental systems and ensure the safety of food and water.
Innovative, label-free analytical approaches make it possible to detect and characterize microplastics with high precision, revealing their composition and distribution at the microscopic level. This enables more accurate monitoring of contamination, supports better risk assessment, and contributes to the development of safer and more sustainable food and water resources.
biotech
Medical diagnostics, for faster diagnosis and improved treatment decisions
Improving medical diagnostics requires faster, more reliable tools to support timely and informed treatment decisions.
Advanced, label-free imaging technologies enable direct analysis of the molecular composition of biological samples, providing precise and reproducible insights without the need for extensive preparation. This approach accelerates diagnostic workflows, enhances accuracy in disease identification, and supports clinicians in making more effective and personalized treatment decisions.
medication
Pharmaceuticals, ensuring higher drug quality and safety
Ensuring the quality and safety of pharmaceutical products requires analytical tools capable of delivering precise and reliable insights throughout the development and production process.
Advanced, label-free imaging techniques enable detailed characterization of chemical composition and structural integrity at the microscopic level, without altering the sample. This supports more accurate quality control, early detection of inconsistencies, and ultimately contributes to safer drugs and more robust pharmaceutical manufacturing processes.
Our history
Cambridge Raman Imaging Limited was founded in March 2018 with the idea to introduce fiber lasers to the biomedical market. With a combination of private and public funding, the company conducted extensive research and development to create a fast and high-resolution imaging solution that surpasses traditional biomedical imaging methods. In 2020, we established a 100% owned subsidiary, CRI S.r.l, in Italy to expand our global outreach and accelerate the commercialization of our technology.
Today, Cambridge Raman Imaging Limited is a recognized and fast-growing player in the field of biomedical imaging, supported by an expanding global network of customers and strategic partners. Building on this strong foundation, we are actively driving the evolution of our technology into industrial quality control applications, with particular focus on the pharmaceutical and environmental sectors. While we continue to push the boundaries of imaging science, we remain steadfast in our long-term vision to lead innovation in both medical and environmental imaging solutions, shaping the future of these fields.
Funding
We’re pleased to be supported by the EU and high-tech investors
Since founding, the company has won four grant applications from the European Graphene Flagship, Horizon Europe, H2020, and Region Lombardy (Italy) and closed its Round 2 equity funding.
Is your company interested in CRI technology?
Statements about future products represent management intentions, but are not to be considered commitments to any specific clinical or non-clinical capability or performance targets.